MedX Names Steve Guillen President and Chief Executive Officer

    Appointment Announced during Annual General Meeting of Shareholders

    MISSISSAUGA, ON, June 27 /CNW/ - MedX Health Corp. (TSXV: MDX) announced
the promotion of Steven T. Guillen to president and chief executive officer of
MedX Health. Guillen was named president and director in April, replacing Phil
Passy, MedX's founder, who passed away earlier this year. The announcement was
made during MedX's annual shareholders meeting held June 25th at The National
Club in Toronto.
    "In just a few short months, Steve has proven his leadership in driving
MedX to the next level," said Gary Van Nest, MedX's Chairman. "His ability to
rally the troops and bring a cohesive purpose to the company is evident. We
applaud the new direction Steve is taking the company and look forward to
strong growth in the next year."
    Prior to joining MedX, Guillen was chief executive officer of OXIS
International, Inc. (OTC BB:OXIS.OB), where he was recruited to lead, and turn
around, an asset-rich publicly traded company with products in diagnostics,
therapeutics, and nutraceuticals. He directed commercial strategy and grew
revenues from $2 million to $6 million in his first year. He also directed an
acquisition and the subsequent merger of the two organizations, including the
relocation of operations and integration of manufacturing, finance, R&D, and
sales & marketing into one site, thereby improving both revenues and
profitability. Prior to that, Guillen was, for eight years, vice president of
Sales & Marketing for Amarin Pharmaceuticals, based in Mill Valley,
California, and Athena Diagnostics, based in Boston, Massachusetts. Prior to
that, he had a number of different roles of increasing responsibility within
Merck & Co, before he was recruited to establish the initial commercial
organization for Athena Neurosciences, as their first director of Sales.
    "The global vision for MedX as the worldwide leader in light technology
is clear," said Mr. Guillen. "We plan to build upon our success in bringing
relief of symptoms in a non-pharmacologic manner in the rehabilitation market
through key partnerships, acquisitions, strong patent protection as well as
developing and commercializing advanced products in the dental and wound-care
markets that will position us to increase revenue in new markets."

    About MedX Health Corp.

    MedX is a leading North American developer and manufacturer of
phototherapy medical devices, including dental, rehabilitation and wound care
products. MedX is the world's only company focusing on developing and
delivering a broad cross-section of technologies and products involved in
healing using light therapy. MedX is committed to advocating for and bringing
the non-invasive, drug-free healing nature of light to people seeking relief
from pain and other physical ailments.
    MedX plans to use the proceeds from its recent public offering to expand
its distribution network; support its marketing program; continue development
of new dental, rehabilitation and wound care products; undertake research and
development for wound care products; and for working capital purposes. In
particular, MedX plans to accelerate the development of a new product aimed at
the rapidly-growing wound care market: its "Photobandage(TM)", a bandage
technology that allows a wound to be bathed in light, designed to enhance the
healing process. The Company intends to license this new technology to one or
more major wound care companies for further development, marketing and sales.

    The TSX Venture Exchange does not accept responsibility for the adequacy
    or accuracy of this press release.

    This press release contains "forward-looking information" within the
meaning of applicable Canadian securities legislation. Such forward-looking
information may include statements regarding the Company's future plans,
objectives, performance, growth, profits, operating expenses or its underlying
assumptions. Generally, forward-looking information can be identified by the
use of forward-looking terminology such as "plans", "expects", or "does not
expect", "is expected", "budget", "scheduled", "estimates", "forecasts",
"intends", "anticipates", or "does not anticipate", or "believes" or
variations of such words and phrases or state that certain actions, events or
results "may", "could", "would", "might", or "will be taken", "occur", or "be
achieved". Forward-looking information is subject to known and unknown risks,
uncertainties and other factors that may cause the actual results, level of
activity, performance or achievements of MedX to be materially different from
those expressed or implied by such forward-looking information, including
uncertainty of successful development of new products, uncertainty of
successful manufacturing or marketing of products, uncertainty of commercial
acceptance of products, uncertainty concerning governmental regulation,
dependency on key employees and relationships, rapid technological changes,
foreign currency fluctuations. MedX does not undertake to update any
forward-looking information, except in accordance with applicable securities

    %SEDAR: 00017466E

For further information:

For further information: Terri Clevenger, Continuum Health
Communications, Phone: (203) 227-0209, Email:; Nelson Smith, Taddle Creek Capital, Phone:
(416) 565-7518, Email:

Organization Profile

MedX Health Corp.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890